MRK vs MSFT: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
VS
Microsoft Corporation · Technology
$429.25
-1.3% upside to fair value
Grade B
High Quality
QuantHub Verdict
MRK has more upside to fair value
(+3.3%).
MRK trades at a lower forward P/E
(22.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
MSFT |
| Current Price |
$114.27 |
$429.25 |
| Fair Value Estimate |
$118.00 |
$423.82 |
| Upside to Fair Value |
+3.3%
|
-1.3%
|
| Market Cap |
$282.2B |
$3,187.4B |
| Forward P/E |
22.4x
|
26.8x
|
| EV / EBITDA |
13.5x
|
17.2x
|
| Price / Sales |
4.3x
|
10.4x
|
| Price / FCF |
20.2x
|
41.2x
|
| Revenue Growth YoY |
+5.0%
|
+16.7%
|
| Gross Margin |
81.9%
|
68.6%
|
| Operating Margin |
27.5%
|
46.7%
|
| Return on Equity |
5.6%
|
33.6%
|
| Dividend Yield |
2.91% |
0% |
| FCF Yield |
4.95%
|
2.43%
|
| Analyst Consensus |
Overweight
|
Strong Buy
|
Investment Thesis
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Microsoft Corporation is a leading technology company specializing in software infrastructure, cloud computing, and productivity solutions. The company benefits from a high-quality business model characterized by durable competitive moats including strong switching costs and intangible assets such as its brand and cloud infrastructure. Under CEO Satya Nadella's leadership since 2014, Microsoft ha…
Accumulation Zones
| Metric |
MRK |
MSFT |
| Zone Low |
$88.50 |
$317.87 |
| Zone High |
$100.30 |
$360.25 |
| In Buy Zone? |
No
|
No
|